Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Donovan

Showing results (431-440 of 694) with videos related to

Pageof 70
Sort By:
Trials|October 21, 2022
Understanding the perspectives of recruiters is key to improving randomised controlled trial enrolment: a qualitative evidence synthesisNicola Farrar, Daisy Elliott, Catherine Houghton, et al.
The Journal of Pharmacy and Pharmacology|November 2, 2005
Oral administration of a decaffeinated green tea (Camellia sinensis) extract did not alter urinary 8-epi-prostaglandin F(2 alpha), a biomarker for in-vivo lipid peroxidationJennifer L Donovan, C Lindsay DeVane, Kenneth D Chavin, et al.
Journal of Clinical Epidemiology|August 19, 2003
Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study)Jenny L Donovan, Tim J Peters, Sian Noble, et al.
Frontiers in Sociology|October 3, 2022
The experience of conducting collaborative and intensive pragmatic qualitative (CLIP-Q) research to support rapid public health and healthcare innovationJeremy Horwood, Christalla Pithara, Ava Lorenc, et al.
BMC Cancer|April 3, 2016
What surgeons tell patients and what patients want to know before major cancer surgery: a qualitative studyAngus G K McNair, F MacKichan, J L Donovan, et al.
BMC Health Services Research|June 9, 2023
Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Joanna C Thorn, Emma L Turner, Eleanor I Walsh, et al.
British Journal of Cancer|January 27, 2011
Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT studyP Dimitropoulou, R M Martin, E L Turner, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 19, 2016
Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality AssuranceM D Mason, R Moore, G Jones, et al.
BJU International|April 19, 2016
Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic reviewPenny F Whiting, Theresa H M Moore, Catherine M Jameson, et al.
Human Pathology|December 3, 2014
Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomasAnja C Roden, Eunhee S Yi, Sarah M Jenkins, et al.
Pageof 70

Showing results (431-440 of 694) with videos related to

Sort By:
Pageof 70
Trials|October 21, 2022
Understanding the perspectives of recruiters is key to improving randomised controlled trial enrolment: a qualitative evidence synthesisNicola Farrar, Daisy Elliott, Catherine Houghton, et al.
The Journal of Pharmacy and Pharmacology|November 2, 2005
Oral administration of a decaffeinated green tea (Camellia sinensis) extract did not alter urinary 8-epi-prostaglandin F(2 alpha), a biomarker for in-vivo lipid peroxidationJennifer L Donovan, C Lindsay DeVane, Kenneth D Chavin, et al.
Journal of Clinical Epidemiology|August 19, 2003
Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study)Jenny L Donovan, Tim J Peters, Sian Noble, et al.
Frontiers in Sociology|October 3, 2022
The experience of conducting collaborative and intensive pragmatic qualitative (CLIP-Q) research to support rapid public health and healthcare innovationJeremy Horwood, Christalla Pithara, Ava Lorenc, et al.
BMC Cancer|April 3, 2016
What surgeons tell patients and what patients want to know before major cancer surgery: a qualitative studyAngus G K McNair, F MacKichan, J L Donovan, et al.
BMC Health Services Research|June 9, 2023
Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Joanna C Thorn, Emma L Turner, Eleanor I Walsh, et al.
British Journal of Cancer|January 27, 2011
Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT studyP Dimitropoulou, R M Martin, E L Turner, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 19, 2016
Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality AssuranceM D Mason, R Moore, G Jones, et al.
BJU International|April 19, 2016
Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic reviewPenny F Whiting, Theresa H M Moore, Catherine M Jameson, et al.
Human Pathology|December 3, 2014
Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomasAnja C Roden, Eunhee S Yi, Sarah M Jenkins, et al.
Pageof 70